Arrowhead Pharmaceuticals has recently announced that the European Commission has granted marketing authorization for Redemplo (plozasiran), an innovative apolipoprotein C III (apoC-III) inhibitor that is already approved in the US for the treatment of adults with familial chylomicronemia syndrome (FCS). The approval was supported by Phase III data demonstrating substantial reductions in triglyceride levels and the incidence of acute pancreatitis. These findings position Redemplo as a promising new treatment option for FCS and may improve patient access to targeted therapy across the EU, says GlobalData, a leading intelligence and productivity platform.

FCS is a rare genetic disorder characterized by severely elevated triglyceride levels due to impaired chylomicron metabolism, placing patients at high risk of recurrent acute pancreatitis and other complications. Current treatment options remain limited, highlighting the need for more effective targeted therapies.

The Phase III PALISADE study evaluated the efficacy and safety of Redemplo in adults with FCS. At month 10, median triglyceride levels were reduced by 80% with Redemplo 25mg; in a pooled analysis across all doses, the incidence rate of acute pancreatitis was reduced by 83%, addressing a significant unmet need in this rare genetic disorder.

Maria Alexandrovich, Pharma Analyst at GlobalData, comments: “The substantial triglyceride reductions observed with Redemplo represent an important advance over conventional triglyceride-lowering treatments, signaling a shift toward targeted treatment approaches such as apoC-III inhibition in FCS management.”

The authorization of Redemplo without requiring genetic confirmation of FCS could facilitate access for a broader population of clinically diagnosed FCS patients and support market uptake.

Alexandrovich continues: “The commercial success of Redemplo will depend on its ability to differentiate from other apoC-III inhibitors, including Tryngolza (olezarsen) and Waylivra (volanesorsen). Further growth opportunities may arise from future label expansion into broader hypertriglyceridemia populations across the US and EU.”

Alexandrovich concludes: “With strong efficacy, a differentiated dosing profile, and the potential to expand access to targeted treatment, Redemplo is well positioned to become an important new treatment option for patients with FCS.”